Abstracts Being Accepted for World’s Premier Multidisciplinary Inflammatory Bowel Disease Event
Atlanta, GA (PRWEB) July 31, 2017 -- Imedex announced today that Advances in Inflammatory Bowel Diseases (AIBD) 2017, taking place in Orlando, FL from November 9-11, is accepting scientific abstracts through August 15, 2017. Established in 2005 and endorsed by leading professional societies including the American College of Gastroenterology and the American Society of Colon and Rectal Surgeons, AIBD is the premier scientific event for healthcare professionals and researchers who study and manage patients with inflammatory bowel disease (IBD).
Over three intensive days, clinicians will gain practice-changing knowledge, researchers will stay abreast of the evolving scientific landscape, nurses and allied healthcare providers will develop and share best practices in multidisciplinary care, and surgeons will observe and gain insight into the latest surgical advances and techniques.
“AIBD remains the preeminent, most attended North American Conference on IBD; bringing together clinicians and clinical/translational investigators to integrate current and future trends in clinical practice,” said expert Stephen B. Hanauer, MD, FACG, Co-chair of the conference.
Abstracts are currently being accepted in the following categories:
Clinical Abstract Categories
Investigator-initiated Controlled Clinical Trials
Investigator-initiated Uncontrolled Clinical Trials
Pharma-initiated Clinical Trials
Procedures and Diagnostics
Epidemiology and Outcomes Research
Patient Care and Complications of Therapy
Clinical Case Reports
Surgery
Pediatric Clinical Abstract Categories
Investigator-initiated Controlled Clinical Trials
Investigator-initiated Uncontrolled Clinical Trials
Pharma-initiated Clinical Trials
Procedures and Diagnostics
Epidemiology and Outcomes Research
Patient Care and Complications of Therapy
Clinical Case Reports
Surgery
Nursing Abstract Categories
Clinical Education
Clinical Basic Research
Clinical Practice
Other
Accepted abstracts will be scheduled for oral or poster presentation and published in a supplement with the February issue of the American Journal of Gastroenterology.
“Imedex and AIBD’s Clinical Organizing Committee remain committed to providing a multidisciplinary scientific forum that encourages sharing and discussion of scientific innovations that will lead to prevention, individualized treatments, and cures for patients with IBD,” says Dan Lowrie, CEO of Imedex.
Individuals interested in submitting abstracts may visit: http://www.advancesinibd.com/abstracts. For more information about the conference, visit http://www.advancesinibd.com.
About Imedex
Imedex is the industry leader in developing and delivering independent, accredited healthcare education. The Company’s programs specializing in gastroenterology, oncology, and hematology are provided through live events around the world as well as through effective online educational opportunities for on-the-go healthcare providers. Imedex’s high-quality scientific programming translates the latest research into clinically relevant information. Our activities facilitate the needs of time-constrained healthcare professionals who are inundated by information through exceptional organization and outstanding educational value — all with a proven and sustained impact on patient care.
Imedex provides over 50,000 E-learning experiences annually and its live conferences have welcomed more than 100,000 attendees since 2001. The Company has a global footprint and operates in the United States, Europe, and Asia.
At Imedex, we believe education is the best medicine®. For more information on Imedex and upcoming conferences, visit us online at http://www.imedex.com, on our E-learning Center at elc.imedex.com, or via email at registration(at)imedex(dot)com.
Brandee Plott, Imedex, http://www.imedex.com, +1 (720) 238-2911, [email protected]
Share this article